Literature DB >> 23715533

Cutaneous epithelioid sarcomalike (pseudomyogenic) hemangioendothelioma: a little-known low-grade cutaneous vascular neoplasm.

Luis Requena1, Carlos Santonja, Jose Luis Martinez-Amo, Carlos Saus, Heinz Kutzner.   

Abstract

IMPORTANCE: Epithelioid sarcomalike (pseudomyogenic) hemangioendothelioma (ES-H) is a recently described and little-known vascular neoplasm that frequently presents with dermatologic lesions. Histopathologic characterization includes sheets or fascicles of plump, spindled and epithelioid, rhabdomyoblastlike neoplastic cells involving the dermis and often extending to subcutaneous tissue. Immunohistochemical analysis reveals neoplastic cells that show a constant immunophenotype characterized by immunoreactivity for cytokeratins and endothelial markers. OBSERVATIONS: We described the clinical, histopathologic, and immunohistochemical features of 2 cases of cutaneous ES-H. Clinical examination revealed multifocal lesions that consisted of erythematous nodules on the leg and foot in case 1 and small perioral papules in case 2. Neoplastic cells had a rhabdomyoblastic appearance, with large nuclei and ample eosinophilic cytoplasm. Immunohistochemical analysis revealed expression of cytokeratin AE1/AE3, CD31, ERG, and FLI-1, with focal and weak positivity for CAM 5.2 and smooth muscle actin. The nuclei of neoplastic cells showed intact expression of INI-1. This immunoprofile, especially the ERG positivity, demonstrated the endothelial nature of proliferating cells.
CONCLUSIONS: We recommend adding the low-grade neoplasm ES-H to the large list of cutaneous vascular proliferations. Dermatologists should be aware of this low-grade cutaneous vascular tumor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715533     DOI: 10.1001/jamadermatol.2013.3190

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  7 in total

1.  The clinicopathological spectrum of pseudomyogenic hemangioendothelioma: report of an additional series with review of the literature.

Authors:  Yuefang Sun; Ming Zhao; I Weng Lao; Lin Yu; Jian Wang
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

2.  A novel treatment for bone lesions of multifocal epithelioid sarcoma-like hemangioendothelioma.

Authors:  Adrian T Davis; A Mary Guo; Nancy J Phillips; David D Greenberg
Journal:  Skeletal Radiol       Date:  2015-01-08       Impact factor: 2.199

3.  Pseudomyogenic Hemangioendothelioma in a 30-Year-Old Man: A Rare Case Report.

Authors:  Chao-Yu Liao; Chao-Kuei Juan; Chi-Shun Yang; Yi-Ju Chen
Journal:  Ann Dermatol       Date:  2019-08-30       Impact factor: 1.444

Review 4.  Malignant Superficial Mesenchymal Tumors in Children.

Authors:  Philippe Drabent; Sylvie Fraitag
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

5.  Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.

Authors:  Narasimhan P Agaram; Lei Zhang; Paolo Cotzia; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

6.  Pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma of the lower limb: report of a rare case.

Authors:  Chuifeng Fan; Lianhe Yang; Xuyong Lin; Enhua Wang
Journal:  Diagn Pathol       Date:  2015-08-28       Impact factor: 2.644

7.  Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma.

Authors:  Jason Joseph; Wei-Lien Wang; Madhavi Patnana; Naveen Ramesh; Robert Benjamin; Shreyaskumar Patel; Vinod Ravi
Journal:  Clin Sarcoma Res       Date:  2015-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.